These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31025286)

  • 1. Human Recombinant VEGFR2D4 Biochemical Characterization to Investigate Novel Anti-VEGFR2D4 Antibodies for Allosteric Targeting of VEGFR2.
    Di Stasi R; De Rosa L; Diana D; Fattorusso R; D'Andrea LD
    Mol Biotechnol; 2019 Jul; 61(7):513-520. PubMed ID: 31025286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and Conformational Characterization of Recombinant VEGFR2 Domain 7.
    Di Stasi R; Diana D; De Rosa L; Fattorusso R; D'Andrea LD
    Mol Biotechnol; 2019 Nov; 61(11):860-872. PubMed ID: 31531759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling.
    Thieltges KM; Avramovic D; Piscitelli CL; Markovic-Mueller S; Binz HK; Ballmer-Hofer K
    Angiogenesis; 2018 Aug; 21(3):533-543. PubMed ID: 29502220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting extracellular domains D4 and D7 of vascular endothelial growth factor receptor 2 reveals allosteric receptor regulatory sites.
    Hyde CA; Giese A; Stuttfeld E; Abram Saliba J; Villemagne D; Schleier T; Binz HK; Ballmer-Hofer K
    Mol Cell Biol; 2012 Oct; 32(19):3802-13. PubMed ID: 22801374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2.
    Erdag B; Balcioglu BK; Bahadir AO; Serhatli M; Kacar O; Bahar A; Seker UO; Akgun E; Ozkan A; Kilic T; Tamerler C; Baysal K
    Biotechnol Appl Biochem; 2011; 58(6):412-22. PubMed ID: 22172104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periplasmic expression optimization of VEGFR2 D3 adopting response surface methodology: antiangiogenic activity study.
    Cao W; Li H; Zhang J; Li D; Acheampong DO; Chen Z; Wang M
    Protein Expr Purif; 2013 Aug; 90(2):55-66. PubMed ID: 23680780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An active murine-human chimeric Fab antibody derived from Escherichia coli, potential therapy against over-expressing VEGFR2 solid tumors.
    Huang J; Liang J; Tang Q; Wang Z; Chen L; Zhu J; Feng Z
    Appl Microbiol Biotechnol; 2011 Sep; 91(5):1341-51. PubMed ID: 21604194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
    Lin YC; Liu CY; Kannagi R; Yang RB
    Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy.
    Ran S; Huang X; Downes A; Thorpe PE
    Neoplasia; 2003; 5(4):297-307. PubMed ID: 14511401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and characterization of a human nanobody against VEGFR-2.
    Ma L; Gu K; Zhang CH; Chen XT; Jiang Y; Melcher K; Zhang J; Wang M; Xu HE
    Acta Pharmacol Sin; 2016 Jun; 37(6):857-64. PubMed ID: 27108602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
    Wicki A; Rochlitz C; Orleth A; Ritschard R; Albrecht I; Herrmann R; Christofori G; Mamot C
    Clin Cancer Res; 2012 Jan; 18(2):454-64. PubMed ID: 22065082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor receptor-2 inhibition in experimental murine colitis.
    Knod L; Donovan EC; Chernoguz A; Crawford KM; Dusing MR; Frischer JS
    J Surg Res; 2013 Sep; 184(1):101-7. PubMed ID: 23688787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling.
    Yang Y; Xie P; Opatowsky Y; Schlessinger J
    Proc Natl Acad Sci U S A; 2010 Feb; 107(5):1906-11. PubMed ID: 20080685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of angiogenesis and tumor growth by recombinant T4 phages displaying extracellular domain of vascular endothelial growth factor receptor 2.
    Zuo S; Dai G; Wang L; Wen Y; Huang Z; Yang W; Ma W; Ren X
    Arch Virol; 2019 Jan; 164(1):69-82. PubMed ID: 30259141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the receptor binding profiles of the vascular endothelial growth factors on their angiogenic features.
    Nieminen T; Toivanen PI; Rintanen N; Heikura T; Jauhiainen S; Airenne KJ; Alitalo K; Marjomäki V; Ylä-Herttuala S
    Biochim Biophys Acta; 2014 Jan; 1840(1):454-63. PubMed ID: 24112971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of recombinant extracellular fragment of vascular endothelial growth factor receptor 2 and specific monoclonal antibodies to this receptor.
    Korchagina AA; Shein SA; Leopol'd AV; Volgina NE; Gurina OI; Lazarenko IP; Antonova OM; Baklaushev VP; Chekhonin VP
    Bull Exp Biol Med; 2014 Jan; 156(3):357-62. PubMed ID: 24771375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structural basis for the function of two anti-VEGF receptor 2 antibodies.
    Franklin MC; Navarro EC; Wang Y; Patel S; Singh P; Zhang Y; Persaud K; Bari A; Griffith H; Shen L; Balderes P; Kussie P
    Structure; 2011 Aug; 19(8):1097-107. PubMed ID: 21827946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy.
    Orleth A; Mamot C; Rochlitz C; Ritschard R; Alitalo K; Christofori G; Wicki A
    J Drug Target; 2016; 24(1):80-9. PubMed ID: 26204325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative interactions between VEGFR2 extracellular Ig-like subdomains ensure VEGFR2 dimerization.
    King C; Wirth D; Workman S; Hristova K
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2559-2567. PubMed ID: 28847506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGFR1(D2) in drug discovery: Expression and molecular characterization.
    Di Stasi R; Diana D; Capasso D; Palumbo R; Romanelli A; Pedone C; Fattorusso R; D'Andrea LD
    Biopolymers; 2010; 94(6):800-9. PubMed ID: 20564033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.